Selank (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency is 1 to 3 subcutaneous administrations daily, with flexible timing in the morning or the evening. Selank is unusual in that daytime use does not impair clarity, because there is no sedation, and evening use does not disrupt natural sleep transitions, because there is no stimulant signature. Most anxiolytics force that trade-off and this one does not. Onset is subtle: some same-day calming, with the deeper shift in stress tolerance building over days as GABAergic gene expression strengthens inhibitory tone, and effects accumulate across repeated exposures. No dependence develops, so breaks exist to maintain receptor sensitivity rather than for safety, and the system drifts back to baseline smoothly at the end of a course with no withdrawal or rebound anxiety. At 5 mg/mL every dose in this protocol falls between 5 and 10 units, so a 30 unit insulin syringe is the sensible barrel here. Sites are rotated systematically across abdomen, thighs, and upper arms. A longer-acting variant, N-Acetyl Selank Amidate, is typically run at 200 to 400 mcg 1 to 2 times daily, with 4 to 8 hours of reported duration per dose against 2 to 4 hours of peak for regular Selank; it has not been through formal clinical trials.

Results Timeline

Sequence described in the research record. Individual response varies.

• Day 1 onward: some same-day calming is reported, but the effect is subtle rather than the immediate switch of a benzodiazepine.
• First days to two weeks: stress tolerance deepens as inhibitory tone strengthens at the gene expression level, and effects accumulate across repeated exposures.
• Day 14: in SSRI augmentation data, 70% of patients showed meaningful anxiety reduction by this point, which is the vulnerable bridge window during antidepressant initiation.
• Day 21: in the phenazepam comparison, the Selank arm reached a 75% responder rate against 30% where phenazepam was stopped without Selank, with the Hamilton anxiety subscale improved about 60% on Selank against about 47% on phenazepam.
• End of course: after 2 to 4 weeks a break of 1 to 2 weeks follows for receptor sensitivity, and the system returns to baseline smoothly with no withdrawal or rebound anxiety.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe, so 250 mcg is 5 units, 300 mcg is 6 units, 400 mcg is 8 units, and 500 mcg is 10 units (0.10 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions, where the powder stays stable for 12 or more months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening, which reduces condensation uptake into the powder.
• Label each vial with the reconstitution date and concentration, and keep it upright in the body of the refrigerator rather than the door, where the temperature swings most.

Supplies Needed

Planning math is based on a 21 day course at 300 mcg twice daily, which is 600 mcg per day and 4.2 mg per week.

Peptide Vials (Selank, 5 mg vial):

• A 21 day course at 300 mcg twice daily totals 12.6 mg of Selank, which is about 3 vials of 5 mg, while a heavier 28 day course at 500 mcg twice daily totals 28 mg and about 6 vials; four 21 day courses across a year come to roughly 12 vials.

Insulin Syringes (U-100):

• Per week: 14 U-100 insulin syringes on the twice daily schedule, ranging from 7 to 21 per week across the 1 to 3 administrations daily the protocol allows. A 30 unit barrel is preferred at these volumes.
• Full cycle: 42 syringes for a 21 day course at twice daily, and about 170 per year across four courses.

Bacteriostatic Water (10 mL bottles):

• At 1.0 mL of bacteriostatic water per 5 mg vial, one 10 mL bottle reconstitutes 10 vials, which covers roughly three 21 day courses, so 2 bottles cover a typical year of four courses.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 28 per week on the twice daily schedule.
• Full cycle: 84 swabs for a 21 day course at twice daily, and about 340 per year across four courses, or two to four boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Not for acute panic. The onset is not fast enough to abort a crisis in progress, and benzodiazepines remain the appropriate acute intervention. Selank is the daily floor-raiser that reduces how often panic begins.
• Cycling is for sensitivity, not safety: 2 to 4 weeks on, 1 to 2 weeks off. No dependence develops and breaks simply preserve receptor sensitivity, so continuous use through a high-stress period is acceptable.
• Onset is subtle and effects accumulate. Anyone expecting an immediate benzodiazepine style effect will be disappointed, because the gene level changes take days to build.
• Standard stacking partners from the master sheet: Semax for balanced focus and calm, where Semax provides cognitive drive and Selank smooths the emotional edge; DSIP, where Selank opens the anxiety gate and DSIP deepens sleep architecture; and GLP-1 agonists, where Selank smooths the emotional baseline during deficit-driven stress.
• Contraindications: known peptide hypersensitivity, pregnancy or breastfeeding given insufficient safety data, and concurrent CNS depressants without medical supervision.
• Regulatory Note: Selank has been a registered pharmaceutical in Russia since 2009, but it is not an approved drug in the United States and is supplied for research purposes only, not for human consumption. Large Western placebo-controlled trials have not been run, an absence that reflects pharmaceutical economics, since the peptide is unpatentable, rather than scientific doubt. The master sheet does not record a WADA classification for this compound.

How This Works

Selank works through three reinforced buffer systems rather than forcing one open. First, an inhibitory tone layer: Selank increases expression of genes encoding GABA receptor subunits and related inhibitory signaling components, and voltage-clamp recordings in rat hippocampal CA1 show enhanced inhibitory postsynaptic potentials by way of interneuron modulation. The fast-braking pathway gets reinforced rather than forced, while the slow-braking pathway that governs muscle relaxation and deep sedation is mostly unchanged, which is why Selank does not produce the lethargic heaviness of alcohol or barbiturates. Second, a stress-buffering peptide layer: Selank slows the breakdown of endogenous enkephalins through enkephalinase inhibition, and preserving these short stress and pain modulating peptides quiets the background noise that amplifies stress reactivity. Third, a mood circuit layer: Selank alters serotonin, dopamine, and metabolite turnover in frontal cortex and hippocampus without producing a stimulant pattern, so the mood-stabilizing effect emerges alongside the anxiolytic effect rather than as a separate program. The net result is a higher threshold for anxious reactivity through reinforced capacity rather than suppression. The system still reacts to meaningful stressors, it just stops overshooting on minor ones, and fatigue, withdrawal, and rebound anxiety do not appear because the braking system is never pushed past its natural range.

Benefits & Side Effects

Observations from the published record.

• Benzodiazepine head to head (Tereshchenko and Medvedev, 2014): in anxiety disorders, Selank continued after a phenazepam taper reached a 75% responder rate at day 21 against 30% where phenazepam stopped with no Selank and 25% where all treatment was withdrawn. The Hamilton anxiety subscale improved about 60% on Selank against about 47% on phenazepam, with no sedation, no dependence, and superior SF-36 quality of life.
• Generalized anxiety disorder across multiple Russian RCTs: anxiety score reductions comparable to benzodiazepines with no sedation, cognitive impairment, or withdrawal, alongside reduced worry, physical tension, and internal unease while concentration was maintained or improved.
• Post-COVID cognitive fatigue (2024 RCT, n=64): Selank at 1.5 mg per day intranasally for 30 days alongside standard neuroprotective care produced superior recovery of mental work capacity, greater reduction in anxiety and depressive symptoms, and better fatigue resolution than controls.
• SSRI augmentation: 70% of patients receiving Selank showed meaningful anxiety reduction by day 14 of antidepressant initiation, with effects persisting 2 weeks after discontinuation, addressing roughly the 40% who experience delayed response or residual symptoms on SSRIs alone.
• Stress-driven eating (Verbenko, 2012) and atopic dermatitis (controlled, n=65): a 14 day course reduced binge frequency and accelerated satiety onset, while in atopic dermatitis Selank added to standard therapy produced about 2.4-fold anxiety reduction against about 1.3-fold in controls, a near doubling of beta-endorphin, and DLQI quality of life gains of about 1.7x against about 1.2x.
• Side effects and tolerability: consistently superior to benzodiazepine comparators in Russian trial data, with no sedation, no cognitive impairment, and no dependence signal. Rare mild headache is reported, as is rare nasal irritation with the intranasal route. Most published data comes from Russian trials with modest sample sizes.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with stress hygiene basics such as sleep, exercise, and breathwork. Selank raises the threshold; lifestyle inputs determine where that threshold sits.
• Moderate caffeine during high-anxiety windows. Selank reduces reactivity but does not override a chronic cortisol and caffeine spiral.
• Sleep 7 to 9 hours. Sleep debt directly amplifies anxious reactivity, and the protocol assumes adequate sleep as its substrate.
• Reduce alcohol during courses and track baseline anxiety weekly. Both substances modulate GABAergic tone, and the shift Selank produces is subtle enough that written tracking captures changes subjective recall misses.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Zozulya AA et al. Selank: anxiolytic peptide with unusual mechanisms (Neurosci Behav Physiol, 2009).
2. Tereshchenko ON et al. (Medvedev VE) Selank vs phenazepam in anxiety disorders (Zh Nevrol Psikhiatr, 2014, PMID 25176261).
3. Seredenin SB et al. Monoamine modulation by Selank (Neurosci Behav Physiol, 2008, PMID 18454096).
4. Pogodina MG, Nikiforova EYu. Selank in post-COVID syndrome (Vrach, 2024).
5. Verbenko VA, Shakina TA. SSRI augmentation with Selank in anxiety-depressive disorders (2019).
6. Kolik LG, Nadorova AV et al. Neuroprotective effects of Selank: systematic review (CNS Neurol Disord Drug Targets, 2017, PMID 29098180).